Published on 24 March 2014
Subsequent entry biologics (biosimilars) in Canada: approaches to interchangeability and the extrapolation of indications and uses
Author(s): Agnes V Klein, MD, DPH, Jian Wang, MD, PhD, Patrick Bedford, BSc, MA
biosimilar, Canada, reference biological product, subsequent entry biologics (SEBs)
DOI: 10.5639/gabij.2014.0303.033
21.759 views